A team headed by researchers at the University of Pennsylvania has figured out a way to reduce the toxicity of Lou Gehrig's disease by slowing neuron dysfunction in animal models. The discovery could offer a new way to treat the disease, also known as amyotrophic lateral sclerosis, or ALS.
Eli Lilly and the nonprofit Project A.L.S. are teaming up to boost the pipeline of potential drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig' disease.
An innovative new approach, drawing on the disciplines of both medical science and data science, offers the promise of an unprecedented breakthrough in the search for a cure for amyotrophic lateral sclerosis.
Forced to remedy an error in a study for a potential ALS drug, Cytokinetics has revealed plans to amend the protocol of the midstage trial with expanded enrollment.
Biogen Idec has been unable to shake off Knopp Neurosciences, from which Biogen licensed a compound against Lou Gehrig's disease that fell short in a recent late-stage study.
Biogen Idec ($BIIB) is reaching into its own pocket to make up for a federal tax that hits its gay employees, The Boston Globe reported. Next year the biotech giant is expected to start padding the pay of homosexual staffers who are taxed, unlike their heterosexual coworkers, on health-insurance contributions for their spouses.
Today the company announced the initiative focused on amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, with plans to funnel more than $10 million over three years into projects from neuroscience experts at institutions such as Columbia University, Harvard University, Rockefeller University and Yale University.
In a study sponsored by the ALS Association, researchers have assessed a blood protein biomarker that could be used to track the progression of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Despite falling short of goals in a Phase II trial, Neuraltus Pharmaceuticals saw enough evidence of efficacy in Lou Gehrig's disease patients on its experimental drug to push forward plans for a late-state study. Its decision to start the Phase III program next year underscores the critical need for new therapies against the muscle-disabling disorder.
Researchers from Brigham and Women's Hospital have found a blood biomarker that could detect amyotrophic lateral sclerosis (ALS), a progressive degenerative neurological disease that affects about 30,000 Americans.